title: Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?".
abstract: I was asked to provide a commentary for "Shouldn't Propranolol be Used to Treat All Hemangiomas?" by Moodley et al. (Aesth Plast Surg, 2015. doi: 10.1007/s00266-015-0557-x ). I commend the authors for implicitly recognizing that it is no longer appropriate to take the laissez faire approach to hemangiomas of infancy. Whilst hemangiomas will eventually improve, they will not necessarily "disappear," as parents are often erroneously counseled. In fact, the larger a hemangioma becomes, the less likely one will be pleased with the ultimate result, whether treated medically or not. The natural process of proliferation followed by involution often produces saggy anetoderma, which, in certain anatomic locations is obvious and draws negative attention.
  
  
  METHODS
  This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.
authors: Vascular Anomalies Program of Lenox Hill Hospital, 210 East 64th Street - 7th Floor, New York, NY, 10065, USA. fblei@nshs.edu.
authors: Francine
authors: F
authors: Blei
mesh_terms: D000818:Animals; D002102:Cadaver; D019317:Evidence-Based Medicine; D006391:Hemangioma; D006801:Humans; D011433:Propranolol
chemical_list: D011433:Propranolol
keywords: Beta-blocker therapy; Hemangioma of infancy; Propranolol